EFS-Web Receipt date: 03/28/2006

10573658 - GAU: 1647

MPZORISCICIONINO 28 MAR 2006

Docket No.: 1912-0330PUS1

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Lisa MCKERRACHER et al.

Application No.: NEW

Confirmation No.: N/A

Filed: March 28, 2006

Art Unit: N/A

For: CLOSTRIDIUM BOTULINUM C3

EXOTRANSFERASE COMPOSITIONS AND METHODS FOR TREATING TUMOUR

**SPREADING** 

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not provided.

Those documents which are marked with a double asterisk (\*\*) next to the Cite No. in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or

EFS-Web Receipt date: 03/28/2006

10573658 - GAU: 1647

10/573658

Application No.: NEW

Docket No.: 1912-0330PUS1

submitted to the Office in a prior application number PCT/CA2004/001763, filed September 29, 2004.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: March 28, 2006

Respectfully submitted,

Mark J. Nuell, Ph.D.

Registration No.: 36,623

BIRCH, STEWART, KOLASCH & BIRCH, LLP

#32.888

8110 Gatehouse Road

Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

## IAPZOREC'OFETITTO 28 MAR 2006

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	NEWU 4 5 / 3 6 5 8	
IN	<b>IFORMATIO</b>	N DI	SCLOSURE	Filing Date	March 28, 2006	
S	STATEMENT BY APPLICANT			First Named Inventor	Lisa MCKERRACHER	
_				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	1912-0330PUS1	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where	
	No.1	Number-Kind Code <sup>2</sup> ( if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
/CMW	AA*	US-20020077283-A1	06-20-2002	Sessa		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Palentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76	
CMW	BA**	CA-2342970-A	10-12-2002			ISR	
CMW	BB**	EP-1177796-A	02-06-2002			ISR	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
/CMW/	CA**	VERSCHUREN, H et al., European Journal of Cell Biology (1997) vol. 73, pp. 182-187.	ISR		
8	CB**	IMAMURA, F et al., Jpn J. Cancer Res. (2000) vol. 91, pp. 811-816	ISR		
	CC**	YOSHIOKA, K et al., FEBS Letters (1995) vol. 372, pp.25-28	ISR		
1 /	CD**	VAN AELST, L et al., Genes & Development (1997) vol. 11, pp. 2295-2322	ISR		
W	CE**	WILDE, C et al., Journal of Biological Chemistry (2000) vol. 275, no.22, pp. 16478-16483	ISR		
/CMW/	CF**	AKTORIES, K et al., Trends in Cell Biology (1995) vol. 5, pp.441-443	ISR		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

Examiner	/Cherie M. Woodward/	Date	09/08/2008
Signature	Gilotto IVI. Evocatvalar	Considered	00/00/2000

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.